An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists

Table 4

Results of the linear model for saccadic peak velocity change from baseline and log body sway change from baseline by treatment with treatment by SPV change from baseline as interaction.

Treatment	ΔSPV-relative relation	Item	Estimate of treatment	Estimate of lorazepam	𝑃 value
TPA023 1.5 mg	ΔSway-ΔSPV	Slope	−0.00048	−0.00305	<0.0001
		Intercept	−0.01316	0.1292	<0.0001
	ΔVASalertness-ΔSPV	Slope	0.03312	0.126	0.0001
		Intercept	0.4551	−4.4739	0.0021
TPACMP2 0.75 mg	ΔSway-ΔSPV	Slope	−0.00027	−0.00305	<0.0001
		Intercept	0.03784	0.1292	0.0009
	ΔVASalertness-ΔSPV	Slope	0.09884	0.126	0.2525
		Intercept	−1.4465	−4.4739	0.0397
SL65.1498 25 mg	ΔSway-ΔSPV	Slope	−0.00128	−0.00305	0.0003
		Intercept	0.0222	0.1292	<0.0001
	ΔVASalertness-ΔSPV	Slope	0.04193	0.126	0.0009
		Intercept	0.2453	−4.4739	<0.0001
	ΔSmooth-ΔSPV	Slope	0.01554	0.1099	<0.0001
		Intercept	−1.4483	−6.2553	<0.0001
Alprazolam 1 mg	ΔSway-ΔSPV	Slope	−0.00204	−0.00305	0.0667
		Intercept	0.001788	0.1292	<0.0001
	ΔVASalertness-ΔSPV	Slope	0.0734	0.126	0.0763
		Intercept	−0.628	−4.4739	0.0254
	ΔTrack-ΔSPV	Slope	0.0747	0.0572	0.1545
		Intercept	0.3023	−4.0742	<0.0001
	ΔSmooth-ΔSPV	Slope	0.08077	0.1099	0.2808
		Intercept	−1.4025	−6.2553	0.0002
Zolpidem 10 mg	ΔSway-ΔSPV	Slope	−0.0033	−0.00305	0.7336
		Intercept	0.06014	0.1292	0.0127
	ΔVASalertness-ΔSPV	Slope	0.1526	0.126	0.5231
		Intercept	−3.2697	−4.4739	0.5219
	ΔTrack-ΔSPV	Slope	0.0489	0.0572	0.6240
		Intercept	−0.9123	−4.0742	<0.0001
	ΔSmooth-ΔSPV	Slope	0.09771	0.1099	0.7412
		Intercept	−3.8439	−6.2553	0.0815